Tema Oncology ETF (NASDAQ:CANC) Sees Significant Decrease in Short Interest

Tema Oncology ETF (NASDAQ:CANC) was the target of a large decline in short interest in March. As of March 31st, there was short interest totalling 1,800 shares, a decline of 18.2% from the March 15th total of 2,200 shares. Based on an average daily volume of 17,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.1% of the shares of the stock are sold short.

Tema Oncology ETF Price Performance

Shares of Tema Oncology ETF stock traded down $0.23 during trading on Monday, reaching $22.96. 3,081 shares of the stock traded hands, compared to its average volume of 11,912. Tema Oncology ETF has a 52-week low of $20.10 and a 52-week high of $30.11. The business has a fifty day simple moving average of $24.32 and a two-hundred day simple moving average of $25.68. The company has a market capitalization of $61.76 million, a price-to-earnings ratio of 20.79 and a beta of 1.11.

Hedge Funds Weigh In On Tema Oncology ETF

An institutional investor recently raised its position in Tema Oncology ETF stock. Thrivent Financial for Lutherans grew its position in shares of Tema Oncology ETF (NASDAQ:CANC) by 29.6% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 517,837 shares of the company’s stock after acquiring an additional 118,328 shares during the quarter. Thrivent Financial for Lutherans owned about 20.31% of Tema Oncology ETF worth $13,156,000 at the end of the most recent reporting period.

About Tema Oncology ETF

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.